30th October, 2024

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir / Madam,

Subject: Update on USFDA inspection at Company's manufacturing facility in Goa, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 21st June, 2024, regarding the routine current Good Manufacturing Practices (cGMP) inspection at Company's manufacturing facility in Goa, India between 10th – 21st June, 2024, we hereby notify that the United States Food and Drug Administration (USFDA) vide communication dated Wednesday, 30th October, 2024 (8:28 p.m. IST) has classified the above referred inspection as Voluntary Action Indicated (VAI).

Please take the above information on record.

Thanking you,

Yours faithfully,
For Cipla Limited
RAJENDRA KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA
Date: 2024.10.30 21:28:19 +05'30'
Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode